Coronavac - 克爾來福2019冠狀病毒病疫苗

In April, Panama approved emergency use of Coronavac.

A total of 12,396 volunteers participated in the study between 21 July and 16 December 2020.

Description: Through the head-to-head comparison, vaccination with BNT162b2 induces significantly higher levels of SARS-CoV-2 specific binding and neutralizing antibody responses when compared to CoronaVac.

Views: 8572 Date: 19.05.2022 Favorited: 27 favorites
Category: DEFAULT

User Comments 3

Post a comment

In June, Thailand's Public Health Ministry stated the vaccine had 71%-91% efficacy against infection by the strain.
The recommendation was given with limited evidence at the time of approval for groups other than healthy adults.

Hot Categories

Latest Comments

    China's Coronavac vaccine was 67 percent effective at preventing symptomatic Covid-19 and 80 percent at preventing death, according to real-life results unveiled Friday from Chile's inoculation.
    By: Freed_o_gram|||||||||
    The first paper, titled Immunogenicity and safety of a third dose, and immune persistence of CoronaVac vaccine in healthy adults aged 18-59 years: interim results from a double-blind, randomized.
    By: BetterCallSal|||||||||
    As per news agencies, China's CoronaVac vaccine, produced by Sinovac, has received WHO's approval for Emergency Use Authorization across the globe. Sinovac is a Beijing-based biopharmaceutical company that has produced the CoronaVac, an inactivated vaccine that works by using killed viral particles to expose the body's immune system to the.
    By: AnoushkaSingh|||||||||
    Factsheet for health workers: Sinovac-CoronaVac COVID-19 vaccine, July 2021. Job aid for COVID-19 vaccine administration: Sinovac-CoronaVac COVID-19 vaccine, July 2021. Vaccination against COVID-19 with the Sinovac-CoronaVac COVID-19 vaccine - A quick guide, July 2021. Facebook Instagram Twitter YouTube.
    By: bhaaay|||||||||
    AsianScientist (Jun. 16, 2020) – Chinese vaccine maker Sinovac Biotech Ltd. announced on Monday that the company’s COVID-19 vaccine candidate, CoronaVac, showed favorable immunogenicity and safety profiles in recently concluded Phase I/II clinical trials. Sinovac’s development of an inactivated vaccine candidate against COVID-19 began in January 2020 in partnership with leading academic.
    By: AnastasiaCisarovna||||||||| - 2022
DISCLAIMER: All models on adult site are 18 years or older. has a zero-tolerance policy against ILLEGAL pornography. All galleries and links are provided by 3rd parties. We have no control over the content of these pages. We take no responsibility for the content on any website which we link to, please use your own discretion while surfing the porn links.
Contact us | Privacy Policy | 18 USC 2257 | DMCA